4653,883 Accrued income taxes17,35111,66517,702 Current portion of long-term debt15,000400,000- Current liabilities of discontinued operations 3,5705,37010,228Total current liabilities566,606922,509452,749Non-current liabilities Long-term debt, less current portion875,442935,000825,000 Non-current deferred income taxes11,90049,34648,694 Other non-current liabilities158,444108,208104,881Total non-current liabilities1,045,7861,092,554978,575Shareholders' equity Controlling interest shareholders' equity:Preferred stock, without par value, 10,000 shares authorized ---Common stock, without par value, 200,000 shares authorized 458,811428,457413,683Accumulated other comprehensive income109,08043,20064,547Retained earnings855,287620,439577,2581,423,1781,092,0961,055,488 Noncontrolling interest1,9211,8441,869Total shareholders' equity1,425,0991,093,9401,057,357$
3,037,491$
3,109,003$
2,488,681Supplemental Disclosures of Balance Sheet Information Related to Continuing OperationsAllowance for doubtful accounts
$
7,618$
8,015$
10,760Working capital
$
693,814$
478,187$
693,556Preferred stock, shares issued and outstanding---Common stock, shares issued and outstanding92,68291,69491,356See accompanying notes to condensed consolidated financial statements.PERRIGO COMPANYCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)(unaudited)Year-To-Date20112010
As Adjusted
(Note 1)Cash Flows (For) From Operating Activities Net income
$
253,627$
174,855 Adjustments to derive cash flowsWrite-off of in-process research and development-14,000Depreciation and amortization76,25751,811Restructuring-7,474Share-based compensation11,52611,184Loss (gain) on sale of business2,151(750)Income tax benefit from exercise of stock options1,621(905)Excess tax benefit of stock transactions(16,256)(5,730)Defer
'/>"/>
SOURCE Perrigo Company Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Related medicine technology :1.
Perrigo Announces FDA Final Approval for Minoxidil Foam - Generic Equivalent to Mens Rogaine® Foam2.
Perrigo Company Announces Quarterly Dividend3.
Perrigos PBM Infant Formula Unit Wins Appellate Judgment Versus Mead Johnson4.
Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets5.
Perrigo Announces Conclusion of the FDA Re-Inspection6.
Perrigo Company to Present at the Barclays Capital 2011 Global Health Care Conference7.
Perrigo Announces Arrival of the FDA for Reinspection Related to the Allegan Facility Warning Letter8.
Perrigo Company to Present at the Citi 2011 Global Health Care Conference9.
Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma10.
Perrigo Enters Into Exclusive Sales and Distribution Agreement With AgaMatrix for Store Brand Blood Glucose Monitoring Products11.
Perrigo Announces Settlement of Rogaine® Foam Patent Litigation